APA (7th ed.) Citation

Beck, D. B., Heiblig, M., Savic, S., Ferrada, M. A., Mekinian, A., Chowdhury, O., . . . Koster, M. J. (2026). PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome. Journal of Clinical Medicine, 15(4), 1426. https://doi.org/10.3390/jcm15041426

Chicago Style (17th ed.) Citation

Beck, David B., et al. "PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome." Journal of Clinical Medicine 15, no. 4 (2026): 1426. https://doi.org/10.3390/jcm15041426.

MLA (9th ed.) Citation

Beck, David B., et al. "PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome." Journal of Clinical Medicine, vol. 15, no. 4, 2026, p. 1426, https://doi.org/10.3390/jcm15041426.